Search Results
Jun 16, 2026, 07:30 ET SpliSense Secures Up to $13 Million from the Cystic Fibrosis Foundation to Advance Phase 2b Study of SPL84 for Cystic Fibrosis
/PRNewswire/ -- SpliSense, a clinical-stage biotechnology company developing transformative RNA-based therapies for pulmonary diseases, today announced that it has entered into a funding agreement with the Cystic Fibrosis Foundation, under which
More news about: SpliSense
Jun 15, 2026, 06:00 ET IDEAYA Biosciences Announces IDE892, a Potential Best-in-Class MTA-Cooperative PRMT5 Inhibitor, Initiates a Phase 1/2 Clinical Combination Study in MTAP-Deleted Pancreatic and Lung Cancers
Biosciences.Loss of MTAP leads to the accumulation of MTA and increased dependence on PRMT5 and MAT2A, two key enzymes involved in methylation and RNA splicing. In MTAP-deleted tumors, this biology establishes a robust synthetic lethal vulnerability that underpins the mechanistic rationale for combining
More news about: IDEAYA Biosciences, Inc.
Jun 15, 2026, 00:00 ET Rznomics Presents Clinical Interim Data for RZ-001 in Recurrent Glioblastoma at ASNO 2026
/PRNewswire/ -- Rznomics Inc., a biopharmaceutical company specializing in the development of RNA-based gene therapies, announced that the Phase 1/2a interim clinical results for 'RZ-001 (Taspitimagene advec)', its RNA editing-based anticancer gene therapy for recurrent glioblastoma (rGBM), were presented
More news about: Rznomics
Jun 13, 2026, 11:40 ET MGI Tech Showcases Expanding Genomics Ecosystem at ESHG 2026 with New IVD Partnering Program and OEM Collaborations
clinical oncology diagnostics, pharmacogenomics, and spatial multi-omics.Dr. Raquel T. Lima from IPATIMUP (Portugal) presented the clinical value of RNA sequencing for detecting actionable gene fusions in solid tumours, improving diagnostic yield and supporting precision oncology decision-making. Prof.
More news about: MGI Tech Co., Ltd.
Jun 12, 2026, 14:05 ET Volta Labs erweitert das Twist-Hybrid-Capture-Portfolio für Callisto™ mit der Einführung von Twist Fast Hyb
Probenvorbereitung mit dem Callisto™ Sample Prep System. Mit einer firmeneigenen Elektrowetting-Technologie bietet Callisto eine vollautomatische DNA- und RNA-Extraktion sowie Bibliotheksaufbereitung für alle gängigen Sequenzierplattformen – darunter Illumina, Oxford Nanopore, PacBio, Element Biosciences, Roche
More news about: Volta Labs
Jun 12, 2026, 09:05 ET Volta Labs Brings the Complete Twist Hybrid Capture Portfolio to Callisto™ with Launch of Twist Fast Hyb
genomic sample preparation with the Callisto™ Sample Prep System. Using proprietary electrowetting technology, Callisto provides fully automated DNA and RNA extraction and library preparation for all major sequencing platforms — including Illumina, Oxford Nanopore, PacBio, Element Biosciences, Roche and Ultima
More news about: Volta Labs
Jun 12, 2026, 04:05 ET Volta Labs Brings the Complete Twist Hybrid Capture Portfolio to Callisto™ with Launch of Twist Fast Hyb
genomic sample preparation with the Callisto™ Sample Prep System. Using proprietary electrowetting technology, Callisto provides fully automated DNA and RNA extraction and library preparation for all major sequencing platforms — including Illumina, Oxford Nanopore, PacBio, Element Biosciences, Roche and Ultima
More news about: Volta Labs
Jun 12, 2026, 03:00 ET Beyond the Double Helix: Phinomics Joins "All Access hosted by Andy Garcia" to Explore Hidden Frontiers in Genetics
living systems are far too complex and multi-layered for that approach. This segment highlights how combining entirely distinct layers of biology, like RNA, proteins, and circular DNA, gives us a far truer window into cellular behavior than mass data collection ever could. This multi-layered view helps explain
More news about: All Access
Jun 11, 2026, 17:15 ET ChronicleBio Is Coming for Chronic Disease: Pioneering Immunologist Joins Elite Scientific Team to Translate Biological Signal into Targeted Therapeutics
non-responders cancel each other out. The company's multi-omic endotype framework addresses this directly, integrating whole-genome sequencing, epigenetics, RNA sequencing, immune profiling, proteomics, and metabolomics to identify biologically coherent patient subgroups before treatment begins. The goal is to
More news about: ChronicleBio
Jun 11, 2026, 09:00 ET Co-Diagnostics Advances Latin American Commercialization Strategy for Co-Dx™ PCR Pro® with Mexico Distributor Agreement
technologies. The Company's technologies are utilized for tests that are designed using the detection and/or analysis of nucleic acid molecules (DNA or RNA). The Company also uses its proprietary technology to design specific tests for its Co-Dx PCR at-home and point-of-care platform (subject to regulatory
More news about: Co-Diagnostics
Jun 11, 2026, 09:00 ET NeuroSense Granted South Korean Patent Covering PrimeC Composition for ALS
target several key mechanisms of ALS and AD, that contribute to neuron degeneration, inflammation, iron accumulation and impaired ribonucleic acid ("RNA") regulation to potentially inhibit the progression of ALS and AD.About ALSAmyotrophic lateral sclerosis ("ALS") is an incurable
More news about: NeuroSense
Jun 11, 2026, 08:26 ET Quintara Biosciences Relocates Boston Lab to Strengthen Service Capacity and Operational Readiness
remain a major focus for us," said Daniel Wang, CEO of Quintara Biosciences. "Our key services like whole plasmid sequencing, amplicon sequencing, and RNA sequencing support workflows that are routine for many research labs, and the region's pace of research makes speed, consistency, and reliable execution
More news about: Quintara Biosciences
Jun 10, 2026, 10:01 ET Developmental and Epileptic Encephalopathies Market to Register Immense Growth at a CAGR of 11.7% During the Forecast Period (2026-2036) Due to the Launch of Next-Generation Gene and Targeted Therapies | DelveInsight
physiological NaV1.1 levels and potentially reducing both seizure frequency and associated non-seizure comorbidities. Unlike gene therapy, this RNA-based approach modulates RNA activity without altering or inserting DNA. The candidate has received orphan drug designation from both the FDA and EMA, along with rare
More news about: DelveInsight Business Research, LLP
Jun 10, 2026, 04:00 ET Servier and n-Lorem Foundation join forces to advance research in rare neurodevelopmental disorders
preclinical candidates, which Servier will advance into clinical development. Antisense oligonucleotides (ASOs) are designed to target disease-causing RNA and may enable highly personalized approaches to treating genetic disorders. This approach opens a new frontier in medicine— addressing the root cause
More news about: Servier
Jun 10, 2026, 04:00 ET Servier and n-Lorem Foundation join forces to advance research in rare neurodevelopmental disorders
preclinical candidates, which Servier will advance into clinical development. Antisense oligonucleotides (ASOs) are designed to target disease-causing RNA and may enable highly personalized approaches to treating genetic disorders. This approach opens a new frontier in medicine— addressing the root cause
More news about: Servier
Jun 09, 2026, 10:01 ET Alcohol-associated Liver Disease Market Gearing Up for Outstanding Expansion at a CAGR of 31.1% During the Forecast Period (2026-2036) | DelveInsight
commercial launch later that year, which could make it the first approved treatment for this indication.GSK's GSK4532990 is an investigational RNA interference (RNAi) therapy being developed by GSK that targets HSD17B13, a gene associated with susceptibility to liver disease. By suppressing hepatic
More news about: DelveInsight Business Research, LLP
Jun 09, 2026, 09:00 ET 10x Genomics Acquires Proteintech Genomics, a Division Within Proteintech Group
research. Today, researchers often rely on multiple vendors and workflows to harmonize RNA and protein analysis in single cell experiments."From day one, Proteintech Genomics was built around the belief that RNA and protein measurements are most powerful when used together. Because our technologies
More news about: 10x Genomics, Inc.
Jun 09, 2026, 09:00 ET NeuroSense Therapeutics Receives Japanese Patent Grant for PrimeC Novel Composition
target several key mechanisms of ALS and AD, that contribute to neuron degeneration, inflammation, iron accumulation and impaired ribonucleic acid ("RNA") regulation to potentially inhibit the progression of ALS and AD.About ALSAmyotrophic lateral sclerosis ("ALS") is an incurable
More news about: NeuroSense
Jun 09, 2026, 08:30 ET AllerGene AI Therapeutics Appoints Biotech Industry Veteran Gad Berdugo to Board of Directors
Management, where he helped guide strategic growth initiatives, partnerships, and financing activities.Mr. Berdugo also brings significant expertise in RNA-based therapeutics and lipid nanoparticle (LNP) delivery technologies, experience that closely aligns with AllerGene's innovative in vivo tLNP mRNA CAR
More news about: AllerGene AI Therapeutics
Jun 08, 2026, 09:15 ET Illumina launches StrataMap Spatial Solution, a powerful end-to-end spatial whole transcriptome research solution
of varying sizes and shapes simultaneously. The solution is species-agnostic and accommodates a broad range of eukaryotic tissue samples and tissue RNA quality. Illumina is actively developing an FFPE-specific solution and targets initial customer enablement in 2027.Scale: StrataMap Spatial
More news about: Illumina, Inc.
Jun 08, 2026, 08:04 ET TransCode Therapeutics to Host R&D Webcast on June 18, 2026
8, 2026 /PRNewswire/ -- TransCode Therapeutics, Inc. (NASDAQ: RNAZ), a clinical-stage oncology company advancing a three-platform pipeline in RNA therapeutics and immuno-oncology, today announced it will host its first live virtual R&D Webcast on Thursday, June 18, 2026, at 10:00 a.m. Eastern
More news about: TransCode Therapeutics, Inc.
Jun 08, 2026, 08:00 ET Argo Biopharma to Present Positive Phase II Updated Results of siRNA Therapeutic BW-20805 for HAE at the EAACI 2026 Congress
June 8, 2026 /PRNewswire/ -- Argo Biopharmaceutical Co., Ltd. (Argo Biopharma), a clinical-stage small interfering RNA (siRNA) therapeutics company, has been selected to present Phase II updated results for BW-20805 at the European Association of Allergy & Clinical
More news about: Argo Biopharmaceutical Co., Ltd
Jun 05, 2026, 20:30 ET Ractigen Therapeutics Announces ADA 2026 Late-Breaking Presentation Highlighting saRNA as a New Frontier in Obesity Control
TherapeuticsRactigen Therapeutics is a clinical-stage biopharmaceutical company innovating next-generation RNA therapeutics, with a primary focus on small activating RNAs (saRNAs) developed through its clinically validated RNA activation (RNAa) technology. Leveraging proprietary delivery platforms such as SCAD™, LiCO™,
More news about: Ractigen Therapeutics
Jun 04, 2026, 07:00 ET ALS United Connecticut Continues Research Investment, Strengthening Momentum Through National Collaboration
affected by ALS."ALS United Connecticut's funding supports the work of AUTTX to advance the development of new molecules that aim to restore normal RNA processing in people with ALS, potentially leading to new treatments for ALS.The research will be led by AUTTX's co-founders Isabelle Draper,
More news about: ALS United
Jun 04, 2026, 07:00 ET Insmed Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)
diseases. The Company's early-stage programs encompass a wide range of technologies and modalities, including gene therapy, AI-driven protein engineering, RNA end-joining, and synthetic rescue.Headquartered in Bridgewater, New Jersey, Insmed has offices and research locations throughout the United States,
More news about: Insmed Incorporated